# A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.

> **NCT07641634** · PHASE1,PHASE2 · RECRUITING · sponsor: **Prolium Bioscience, Inc** · enrollment: 44 (estimated)

## Conditions studied

- Healthy Volunteers
- Systemic Sclerosis (SSc)
- Scleroderma, Systemic
- Scleroderma

## Interventions

- **DRUG:** PRO-203
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07641634
- **Lead sponsor:** Prolium Bioscience, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-27
- **Primary completion:** 2027-01
- **Final completion:** 2028-01
- **Target enrollment:** 44 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07641634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07641634, "A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07641634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*